Fisher & Paykel Healthcare Corporation Limited announced today that it is reactivating its dividend reinvestment plan (DRP) for eligible shareholders residing in New Zealand, Australia and the United Kingdom.
Under the reactivated DRP, eligible shareholders may elect to reinvest all or part of their cash dividends in additional shares. A 3% discount will be applied when determining the price per share of shares issued under the DRP and will be applied in respect of the 2023 interim dividend and future dividends, until such time as the directors determine otherwise.
Shareholders that previously opted into the plan will remain enrolled unless they terminate their participation online at https://investorcentre.linkgroup.nz/ or by completing a cancellation form available upon request from the company’s registrar, Link Market Services.
Shareholders not previously enrolled who wish to participate in respect of the FY2023 interim dividend will need to opt into the plan via Link Market Services’ website at https://investorcentre.linkgroup.nz/ or return a physical participation form before 5pm on 12 December 2022. The plan offer document and participation form are available on the company’s website at www.fphcare.com/drp.
The strike price is calculated as the volume-weighted average sale price for an ordinary share, calculated on all price-setting trades of shares which took place through the NZX Main Board over a period of five trading days immediately following the dividend record date of 9 December 2022. The company will issue an announcement of the strike price, inclusive of the 3% discount, once calculated.
Fisher & Paykel Healthcare first introduced a dividend reinvestment plan in 2009 before suspending it in 2019.
For more information, please contact Link Market Services at firstname.lastname@example.org or +64 9 375 5998.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Media & Investor Contacts
GM Corporate Communications
+64 (0) 21 713 911
Investor Relations Manager
+64 (0) 27 807 8073
Authorised by Fisher & Paykel Healthcare Corporation Limited’s Board of Directors.
Fisher & Paykel Healthcare reactivates dividend reinvestment plan
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
The heating and humidifying of respiratory gases is crucial for intubated patients. Learn about humidification devices, including active and passive.
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Noninvasive respiratory support that provides a continuous distending pressure
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment